Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 14000 shares traded. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The business has a 50-day moving average of C$0.01 and a two-hundred day moving average of C$0.01. The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46. The company has a market cap of C$663,150.00, a P/E ratio of -0.50 and a beta of -0.02.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
See Also
- Five stocks we like better than Aequus Pharmaceuticals
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Growth Stocks: What They Are, Examples and How to Invest
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What is the Shanghai Stock Exchange Composite Index?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
